Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Children's Hospital at Downstate
mi
from
Brooklyn, NY
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Children's Hospital at Downstate
mi
from
Brooklyn, NY
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Children's Hospital of Pittsburgh - University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Children's Hospital of Pittsburgh - University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
St. Jude Childrens Research Hosp, Memphis
mi
from
Memphis, TN
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
St. Jude Childrens Research Hosp, Memphis
mi
from
Memphis, TN
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
mi
from
Dallas, TX
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
mi
from
Dallas, TX
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Baylor School of Medicine
mi
from
Houston, TX
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Baylor School of Medicine
mi
from
Houston, TX
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Children's Hospital and Regional Medical Center - Seattle
mi
from
Seattle, WA
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia
A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Children's Hospital and Regional Medical Center - Seattle
mi
from
Seattle, WA
MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme
Quantitative Assessment of the Early and Late Effects of Radiation and Chemotherapy on Glioblastoma Using Multiple MRI Techniques
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme
Quantitative Assessment of the Early and Late Effects of Radiation and Chemotherapy on Glioblastoma Using Multiple MRI Techniques
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma
A Phase I Trial of Vorinostat in Combination With Bevacizumab and Irinotecan in Recurrent Glioblastoma
Status: Archived
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma
A Phase I Trial of Vorinostat in Combination With Bevacizumab and Irinotecan in Recurrent Glioblastoma
Status: Archived
Updated: 1/1/1970
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
BrUOG-Brain-223:A Study of PPX (CT-2103), Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors (CTI # CT2103)
BrUOG-Brain-223-A Phase II Study of PPX (CT-2103), Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors (CTI # CT2103) Principal Investigator: Howard Safran, M.D.
Status: Archived
Lifespan Hospitals
mi
from
Providence, RI
BrUOG-Brain-223:A Study of PPX (CT-2103), Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors (CTI # CT2103)
BrUOG-Brain-223-A Phase II Study of PPX (CT-2103), Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors (CTI # CT2103) Principal Investigator: Howard Safran, M.D.
Status: Archived
Updated: 1/1/1970
Lifespan Hospitals
mi
from
Providence, RI
Measuring Non-Enhancing Glioblastoma Progression
Quantifying Progression of Non-Enhancing Tumor in Patients With Recurrent Glioblastoma Treated With Antiangiogenic Agents
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Measuring Non-Enhancing Glioblastoma Progression
Quantifying Progression of Non-Enhancing Tumor in Patients With Recurrent Glioblastoma Treated With Antiangiogenic Agents
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Updated: 1/1/1970
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Updated: 1/1/1970
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Updated: 1/1/1970
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Children's Hospital at Downstate
mi
from
Brooklyn, NY
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Updated: 1/1/1970
Children's Hospital at Downstate
mi
from
Brooklyn, NY
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Updated: 1/1/1970
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Medical College of Wisconsin
mi
from
Milwaukee, WI
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Updated: 1/1/1970
Medical College of Wisconsin
mi
from
Milwaukee, WI
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status
Cilengitide in Subjects With Newly Diagnosed Glioblastoma Multiforme and Unmethylated MGMT Gene Promoter - a Multicenter, Open-label Phase II Study, Investigating Two Cilengitide Regimens in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy).
Status: Archived
US Medical Information 888-275-7376
mi
from
Rockland, MA
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status
Cilengitide in Subjects With Newly Diagnosed Glioblastoma Multiforme and Unmethylated MGMT Gene Promoter - a Multicenter, Open-label Phase II Study, Investigating Two Cilengitide Regimens in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy).
Status: Archived
Updated: 1/1/1970
US Medical Information 888-275-7376
mi
from
Rockland, MA
BTC Neuropsychological Database
BTC Neuropsychological Database:Prospective Study
Status: Archived
Duke Univ Med Ctr
mi
from
Durham, NC
BTC Neuropsychological Database
BTC Neuropsychological Database:Prospective Study
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
mi
from
Durham, NC
Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors
Status: Archived
University of Pittsburg Medical Center
mi
from
Pittsburgh, PA
Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
University of Pittsburg Medical Center
mi
from
Pittsburgh, PA
Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors
Status: Archived
Cancer Therapy and Research Center
mi
from
San Antonio, TX
Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Cancer Therapy and Research Center
mi
from
San Antonio, TX
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Updated: 1/1/1970
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
AIDS Associated Malignancies Clinical Trials Consortium
mi
from
Washington,
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Updated: 1/1/1970
AIDS Associated Malignancies Clinical Trials Consortium
mi
from
Washington,
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Georgetown Univ Med Ctr
mi
from
Washington,
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Updated: 1/1/1970
Georgetown Univ Med Ctr
mi
from
Washington,
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Updated: 1/1/1970
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Siteman Cancer Center
mi
from
St. Louis, MO
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Updated: 1/1/1970
Siteman Cancer Center
mi
from
St. Louis, MO
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Montefiore Medical Center
mi
from
Bronx, NY
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Updated: 1/1/1970
Montefiore Medical Center
mi
from
Bronx, NY
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Updated: 1/1/1970
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Pennsylvania Oncology Hematology Associates
mi
from
Philadelphia, PA
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Updated: 1/1/1970
Pennsylvania Oncology Hematology Associates
mi
from
Philadelphia, PA
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Virginia Mason Medical Center
mi
from
Seattle, WA
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Updated: 1/1/1970
Virginia Mason Medical Center
mi
from
Seattle, WA
Apollo Overstitch, a Treat and Resect Model
Evaluation of a Novel Endoscopic Suturing Device in a Treat and Resect Model
Status: Archived
Case Western Reserve Univ
mi
from
Cleveland, OH
Apollo Overstitch, a Treat and Resect Model
Evaluation of a Novel Endoscopic Suturing Device in a Treat and Resect Model
Status: Archived
Updated: 1/1/1970
Case Western Reserve Univ
mi
from
Cleveland, OH
Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase 2 Study of Verubulin With Radiation Therapy and Temozolomide in Subjects Newly Diagnosed With Glioblastoma Multiforme
Status: Archived
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase 2 Study of Verubulin With Radiation Therapy and Temozolomide in Subjects Newly Diagnosed With Glioblastoma Multiforme
Status: Archived
Updated: 1/1/1970
University of Texas Health Science Center at Houston
mi
from
Houston, TX
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
A Phase 2 Study of MEDI-575 in Adult Subjects With Recurrent Glioblastoma Multiforme
Status: Archived
Clinical Research Facility
mi
from
San Diego, CA
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
A Phase 2 Study of MEDI-575 in Adult Subjects With Recurrent Glioblastoma Multiforme
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
San Diego, CA
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
A Phase 2 Study of MEDI-575 in Adult Subjects With Recurrent Glioblastoma Multiforme
Status: Archived
Clinical Research Facility
mi
from
Evanston, IL
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
A Phase 2 Study of MEDI-575 in Adult Subjects With Recurrent Glioblastoma Multiforme
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Evanston, IL
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
A Phase 2 Study of MEDI-575 in Adult Subjects With Recurrent Glioblastoma Multiforme
Status: Archived
Clinical Research Facility
mi
from
Ayer, MA
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
A Phase 2 Study of MEDI-575 in Adult Subjects With Recurrent Glioblastoma Multiforme
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Ayer, MA
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
A Phase 2 Study of MEDI-575 in Adult Subjects With Recurrent Glioblastoma Multiforme
Status: Archived
Clinical Research Facility
mi
from
Bronx, NY
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
A Phase 2 Study of MEDI-575 in Adult Subjects With Recurrent Glioblastoma Multiforme
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bronx, NY
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
A Phase 2 Study of MEDI-575 in Adult Subjects With Recurrent Glioblastoma Multiforme
Status: Archived
Clinical Research Facility
mi
from
Akron, OH
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
A Phase 2 Study of MEDI-575 in Adult Subjects With Recurrent Glioblastoma Multiforme
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Akron, OH
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
A Phase 2 Study of MEDI-575 in Adult Subjects With Recurrent Glioblastoma Multiforme
Status: Archived
Clinical Research Facility
mi
from
Allentown, PA
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
A Phase 2 Study of MEDI-575 in Adult Subjects With Recurrent Glioblastoma Multiforme
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Allentown, PA
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
A Phase 2 Study of MEDI-575 in Adult Subjects With Recurrent Glioblastoma Multiforme
Status: Archived
Clinical Research Facility
mi
from
Chattanooga, TN
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
A Phase 2 Study of MEDI-575 in Adult Subjects With Recurrent Glioblastoma Multiforme
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Chattanooga, TN
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
A Phase 2 Study of MEDI-575 in Adult Subjects With Recurrent Glioblastoma Multiforme
Status: Archived
Clinical Research Facility
mi
from
Bellingham, WA
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
A Phase 2 Study of MEDI-575 in Adult Subjects With Recurrent Glioblastoma Multiforme
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bellingham, WA
A Study of GSK2118436 in BRAF Mutatant Metastatic Melanoma to the Brain
BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain
Status: Archived
GSK Investigational Site
mi
from
Anaheim, CA
A Study of GSK2118436 in BRAF Mutatant Metastatic Melanoma to the Brain
BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Anaheim, CA
A Study of GSK2118436 in BRAF Mutatant Metastatic Melanoma to the Brain
BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain
Status: Archived
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
A Study of GSK2118436 in BRAF Mutatant Metastatic Melanoma to the Brain
BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain
Status: Archived
Updated: 1/1/1970
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
A Study of GSK2118436 in BRAF Mutatant Metastatic Melanoma to the Brain
BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain
Status: Archived
GSK Investigational Site
mi
from
Knoxville, TN
A Study of GSK2118436 in BRAF Mutatant Metastatic Melanoma to the Brain
BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Knoxville, TN
A Study of GSK2118436 in BRAF Mutatant Metastatic Melanoma to the Brain
BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain
Status: Archived
GSK Investigational Site
mi
from
Kennewick, WA
A Study of GSK2118436 in BRAF Mutatant Metastatic Melanoma to the Brain
BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Kennewick, WA
Multidrug Resistance Proteins in Patients Enrolled in Clinical Trials Outside of the National Cancer Institute Center for Cancer Research
Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
Status: Archived
Arizona Clinical Research Center, Inc.
mi
from
Tucson, AZ
Multidrug Resistance Proteins in Patients Enrolled in Clinical Trials Outside of the National Cancer Institute Center for Cancer Research
Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
Status: Archived
Updated: 1/1/1970
Arizona Clinical Research Center, Inc.
mi
from
Tucson, AZ
Multidrug Resistance Proteins in Patients Enrolled in Clinical Trials Outside of the National Cancer Institute Center for Cancer Research
Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Multidrug Resistance Proteins in Patients Enrolled in Clinical Trials Outside of the National Cancer Institute Center for Cancer Research
Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Multidrug Resistance Proteins in Patients Enrolled in Clinical Trials Outside of the National Cancer Institute Center for Cancer Research
Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
Status: Archived
Siteman Cancer Center
mi
from
St. Louis, MO
Multidrug Resistance Proteins in Patients Enrolled in Clinical Trials Outside of the National Cancer Institute Center for Cancer Research
Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
Status: Archived
Updated: 1/1/1970
Siteman Cancer Center
mi
from
St. Louis, MO
Multidrug Resistance Proteins in Patients Enrolled in Clinical Trials Outside of the National Cancer Institute Center for Cancer Research
Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
Status: Archived
Children's Hospital of Pittsburgh - University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Multidrug Resistance Proteins in Patients Enrolled in Clinical Trials Outside of the National Cancer Institute Center for Cancer Research
Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
Status: Archived
Updated: 1/1/1970
Children's Hospital of Pittsburgh - University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Multidrug Resistance Proteins in Patients Enrolled in Clinical Trials Outside of the National Cancer Institute Center for Cancer Research
Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
Status: Archived
Cancer Centers of the Carolinas - Faris Road
mi
from
Greenville, SC
Multidrug Resistance Proteins in Patients Enrolled in Clinical Trials Outside of the National Cancer Institute Center for Cancer Research
Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
Status: Archived
Updated: 1/1/1970
Cancer Centers of the Carolinas - Faris Road
mi
from
Greenville, SC